QQ客服 官方微博 反馈留言

	Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials
	Zhang, Hongliang; Zhao, Jie; Xu, Yanlu; Zhang, Wenjia; Sui, Yonggang; Liu, Qingrong; Wang, Yubin; Liu, Zhihong; Gao, Runlin; Wu, Yongjian
	2019
卷号	16期号:5页码:421-427
关键词	Ischemia driven target lesion revascularization patient-oriented composite endpoints device-oriented composite endpoints ischemia revascularization everolimus bioresorbable stent metallic stent
ISSN号	1743-4440
DOI	10.1080/17434440.2019.1610389
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6341877
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhang, Hongliang,Zhao, Jie,Xu, Yanlu,et al. Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials[J],2019,16(5):421-427.
APA	Zhang, Hongliang.,Zhao, Jie.,Xu, Yanlu.,Zhang, Wenjia.,Sui, Yonggang.,...&Wu, Yongjian.(2019).Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials.,16(5),421-427.
MLA	Zhang, Hongliang,et al."Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials".16.5(2019):421-427.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。